Effect of monosodium olpadronate on osteoclasts and megakaryocytes: An in vivo study

Journal of Musculoskeletal Neuronal Interactions

Volumn 9, Issue 2, 2009, Pages 109-120

  Escudero, N D ^a   Lacave, M ^a   Ubios, A M ^a   Mandalunis, Patricia M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Bisphosphonates; Bone remodelling; Megakaryocyte; Osteoclast; RANKL

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; OLPADRONIC ACID; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; ACID PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; ISOENZYME; TARTRATE-RESISTANT ACID PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BASOPHIL; BONE MARROW; BONE MASS; CELL COUNT; CELL NUCLEUS; CELL POLARITY; CELL SIZE; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; FEMALE; FEMUR; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY STRUCTURE; LIVER STRUCTURE; MEGAKARYOCYTE; MORPHOMETRICS; NICK END LABELING; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; RAT; SPLEEN WEIGHT; TIBIA; WISTAR RAT; ANIMAL; METABOLISM; PHYSIOLOGY;

ACID PHOSPHATASE; ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; ISOENZYMES; MEGAKARYOCYTES; OSTEOCLASTS; RANK LIGAND; RATS; RATS, WISTAR;

EID: 68849111025     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Hiroi-Furuya E, Kameda T, Hiura K, Mano H, Miyazawa K, Nakamaru Y, Watanabe-Mano M, Okuda N, Shimada J, Yamamoto Y, Hakeda Y, Kumegawa M. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate- mature osteoclasts. Calcif Tissue Int 1999;64:219-223 (Pubitemid 29107239)
2. Van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-111 (Pubitemid 29500472)
3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate syntase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-242
4. Van Beek ER, Löwik CWGM, Papapoulos SE. Bisphosphonates supress bone resorption by a direct effect on early osteoclast precursors without affecting the osteogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002;30:64-70.
5. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17:137-144
6. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya N, Abe M, Yuda Y, Konno F, Barbier A, Suda T. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 1997;20:399-404. (Pubitemid 27230443)
7. Koshihara Y, Kodama S, Ishibashi H, Azuma Y, Ohta T. Reversibility of alendronate-induced contraction in human osteoclast-like cells formed from bone marrow cells in culture. J Bone Miner Metab 1999;17:98-107. (Pubitemid 29258478)
8. Ito M, Amizuka N, Nakajima T, Ozawa H. Ultrastructural and citochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone 1999;25:447-452 (Pubitemid 29424238)
9. Benford HL, Mc Gowan WA, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced Caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28:465-473
10. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker for bone resorption. J Bone Miner Res 2000;15:1337-1345 (Pubitemid 30413866)
11. Garnero P, Delmas PD. Biochemical markers of bone turnover: clinical usefulness in osteoporosis. Ann Biol Clin 1999;57:137-148 (Pubitemid 29158626)
12. Compston JE. Bone and bone marrow: a functional unit. J Endocrinol 2002;173:387-393
13. Yin T, Li H. The stem cell niches in bone. J Clin Invest 2006;116:1195-1201
14. Chagraoui H, Sabri S, Capron C, Villeval JL, Vainchenker W, Wedling F. Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. Exp Hematol 2003;31:1081-1088 (Pubitemid 37329752)
15. Bord S, Frith E, Ireland DC, Scott MA, Craig JI, Compston JE. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. Br J Haematol 2004;126:244-251 (Pubitemid 38961944)
16. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JMW, Niforas P, Ng KW, Martin TJ, Guillespie MT. Localization of RANKL (receptor activator of NFκB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999;25:525-534 (Pubitemid 29469458)
17. Wakikawa T, Shioi A, Hino M, Inaba M, Nishizawa Y, Tatsumi N, Morii H, Otani S. Thrombopoietin inhibits in vitro osteoclastogenesis from murine bone marrow cells. Endocrinology 1997;138:4160-4166
18. Villebal JL, Cohen Solal K, Tulliez M, Giraudier S, Guichard J, Burstein SA, Cramer EM, Vainchenker W, Wendling F. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997;90:4369-4383 (Pubitemid 27508443)
19. Kacena MA, Gundberg CM, Nelson T, Horowitz MC. Loss of the transcription factor p45 NF-E2 results in a developmental arrest of megakaryocyte differentiation and the onset of a high bone mass phenotype. Bone 2005;36:215-223 (Pubitemid 40283578)
20. Kacena MA, Shivdasani RA, Wilson K, Xi Y, Troiano N, Nazarian A, Gundberg CM, Bouxsein ML, Lorenzo JA, Horowitz MC. Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res 2004;19:652-660 (Pubitemid 41071226)
21. Kacena MA, Nelson T, Clough ME, Lee SK, Lorenzo JA, Gundberg CM, Horowitz MC. Megakaryocyte-mediated inhibition of osteoclast development. Bone 2006;39:991-999
22. Kacena MA, Gundberg CM, Horowitz MC. A reciprocal regulatory interaction between megakaryocytes, bone cells, and hematopoietic stem cells. Bone 2006;39:978-984 (Pubitemid 44528390)
23. Garimella R, Kacena MA, Tague SE, Wang J, Horowitz MC. Expresión of bone morphogenetic proteins and their receptors in the bone marrow megakaryocytes of GATA-1low mice: a posible rol in osteosclerosis. J Histochem Cytochem 2007;55:745-752 (Pubitemid 46981771)
24. Beeton CA, Bord S, Ireland D, Compston JE. Osteoclast formation and bone resorption are inhibited by megakaryocytes. Bone 2006;39:985-990 (Pubitemid 44528392)
25. Nakamura M, Yagi H, Endo Y, Kosugi H, Ishi T, Itoh T. A time kinetic study of the effect of aminobisphosphonate on murine haemopoiesis. Br J Haematol 1999;107:779-790 (Pubitemid 30020151)
26. Alves-Rosa F, Vermeulen M, Cabrera J, Stanganelli C, Capozzo A, Narbaitz M, Van Rooijen N, Palermo M, Isturiz MA. Macrophage depletion following liposomal- encapsulated clodronate (LIP-CLOD) injection enhaces megakaryocytopoietic and thrombopoietic activities in mice. Br J Haematol 2003;121:130-138 (Pubitemid 36461279)
27. Landoni VI, Vermeulen M, Van Rooijen N, Gomez S, Palermo S, Isturiz MA, Alves-Rosa F. Macrophage derive signalling regulates negatively the megakaryocyte compartment. Cell Mol Biol (Noisy le Grand) 2004; 50 Online Pub:OL667-75.
28. Giuliani AL, Graldi G, Veronesi M, Unis L, Previato A, Lorenzini F, Grandini G, Bergamini C, Vanara F, Wiener E, Wickramasinghe SN, Berti G. Aging of red blood cells and impaired erythropoiesis following prolonged administration of dichloromethylene diposphonate containing liposomes in rats. Eur J Haematol 2005;75:406-416 (Pubitemid 41445081)
29. Kunzman V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999; 340:737-738
30. Thompson K, Rogers M. Bisphosphonates and γδ Tcells: new insights into old drugs. BoneKEy-Osteovision 2006;3:5-13. http://www.bonekey- ibms.org/cgi/content/full/ibmske
31. Roldan EJ, Perez Llore A, Ferretti JL. Olpadronate: a new amino-bisphosphonate for the treatment of medical osteopathies. Expert Opin Investig Drugs 1998;7:1521-1538 (Pubitemid 28408814)
32. Mautalén C, Gonzalez D. Short-term therapy with oral olpadronate in very active Paget's disease. Bone 1999; 24:5(s)93S.
33. Zeni S, Gomez Acotto C, Di Gregorio S. Olpadronate prevents cortical and trabecular bone loss induced by supraphysiological dosis of thyroxine in ovariectomized rats. Medicina (B. Aires) 1998;58:453-455 (Pubitemid 28516822)
34. Tomat A, Gamba CA, Mandalunis PM, De Grandi MC, Somoza J, Friedman S, Zeni S. Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Neuronal Interact 2005;5:174-181 (Pubitemid 41419025)
35. Goya JA, Paez HA, Mandalunis PM. Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats. J Periodontol 2006;77:1-6.
36. Ferretti JL, Mondelo N, Capozza RF, Cointry GR, Zanchetta JR, Montuori E. Effects of large dosis of olpadronate (dimethyl pamidronate) on mineral density, cross-sectional architecture and mechanical properties of rat femurs. Bone 1995;16(Suppl.):285S-293S.
37. Bernhart FW, Tomarelli RM. A salt mixture supplying the National Research Council estimates of the mineral requirements of the rat. J Nutr 1966;89:495-500.
38. Minkin C. Bone Acid Phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast Function. Calcif Tissue Int 1982;34:285-290
39. Gavrieli Y, Sherman Y, Ben Sasson SA. Identification of programmed cell death in situ via specific binding of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
40. Parfitt AM, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry nomenclature, symbols and units: report of the ASBMR Histomorphometry Nomenclature Comitee. J Bone Min Res 1987;2:595-610.
41. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257
42. Miller SC, Jee WS. Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) effects on growth and modeling of the rat tibia. Calciff Tissue Res 1975;18:215-231
43. Sudhoff H, Jung JY, Ebmeyer J, Faddis BT, Hildman H, Chole RA. Zoledronic acid inhibits osteoclastogénesis in vitro and in a mouse model of inflammatory osteolysis. Ann Otol Rhinol Laryngol 2003;112:780-786
44. Keles A, Grunes B, Difuria C, Gagari E, Srinivasan V, Darendeliler MA, Muller R, Kent R Jr, Stashenko P. Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force. Eur J Oral Sci 2007;115:131-136
45. Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, Lindsay R, Dempster DW. Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res 1998;13:1721-1729
46. Miller SC, Jee WS, Kimmel DB, Woodbury L. Ethane -hydroxy-1, 1-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei. Calciff Tissue Res 1977;22:243-252 (Pubitemid 8046588)
47. Marshall MJ, Holt I, Davie MWJ. Osteoclast recruitment in mice is stimulated by (3-amino1-hydroxypropylidene)- 1,1bisphosphonate. Calcif Tissue Int 1993;8:45-50.
48. Endo Y, Nakamura M, Kikuchi T, Shinoda H, Takeda Y, Nitta Y, Kumagai K. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo. Calcif Tissue Int 1993;52:248-254 (Pubitemid 23090721)
49. Smith EJ, Mc Evoy A, Little DG, Baldock PA, Eisman JA, Gardiner EM. Transient retention of endochondral cartilaginous matrix with bisphosphonates treatment in a long-term rabbit model of distraction osteogénesis. J Bone Miner Res 2004;19:1698-1705
50. Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009;1:360:53-62.
51. Landoni VI, Vermeulen M, Van Rooijen N, Gomez S, Palermo M, Isturiz MA, Alves-Rosa F. Macrophage derived signaling regulates negatively the megakaryocyte compartment. Cell Mol Biol (Noisy-le-grand) 2004; 50 Online Pub:OL667-75.
52. Thiede MA, Smock SL, Petersen DN, Grasser WA, Thompson DD, Nishimoto SK. Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology 1994;135:929-937
53. Bord S, Frith E, Ireland DC, Scott MA, Craig JIO, Compston JE. Megakaryocytes modulate osteoblast synthesis of type-1 collagen, osteoprotegerin, and RANKL. Bone 2005;36:812-818
54. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates promote apoptosis in murine osteoclast in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487